AtheroGenics (AGIX) April option implied volatility Elevated at 155
More News related to AGIX
- AtheroGenics (AGIX) Cuts Headcount by 40%; to Record One-Time Charge of $400K in Q3
- AtheroGenics (AGIX) Receives Delisting Notification From NASDAQ
- Pre-Open Movers 4/14: Circuit City (CC) Surges on Blockbuster Bid, Wachovia (WB) Sinks on Losses/Capital Raise
- AtheroGenics (AGIX) Reports Positive Preliminary Results from Phase 3 Trial of ANDES
- Unusual 11 Mid-Day Movers 3/4: STEN, LF, PRAN, FINL Higher; TSRA, OMPI, JTX, THRX Lower
More News related to FDA
- Teva Pharma (TEVA) Gets Final U.S. FDA Approval for Generic Prevacid
- Mylan (MYL) Gets FDA Ok for Generic Prevacid
AtheroGenics (Nasdaq: AGIX) : AGIX focuses on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases. Top line data from the ARISE Phase 3 trial on AGI-1067 is expected in early 2007. CART-2 data on AGI-1067 is expected this quarter. AGIX November option implied volatility is at 69, January is at 93, April is at 155 according to Track Data, suggesting price fluctuations are expected in early 2007. Paul Foster
Related Categories
FDAOptions
Stocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
